Claim your CPD points
We ask Deputy Chief Actuary and General Manager Pricing at Medibank, Adam Stolz, what it was like working on the Vitality program by AIA in Australia, and about the big challenges and opportunities facing the health insurance industry.
I am responsible for pricing, including Medibank's pricing strategy, as well as actuarial advice for portfolio initiatives including new products, new benefits and PHI reforms. This advice includes consideration of both customer value and financial impacts.
The biggest challenge currently is improving affordability, while maintaining the high level of health outcomes across both the public and private system that we currently have in Australia. This is not an easy challenge, and so we need different and innovative ways of thinking as well as strong collaboration across the health system.
New business and funding models that reward health outcomes and not just activity is a shift change that is needed - we should be incentivising efforts in this direction. Without the right incentives in place, it may be difficult for new, worthwhile innovations to thrive.
People are inherently interested in improving their health and wellbeing, and many will respond positively if they are rewarded for doing so. If the rewards are compelling by sharing the value created with customers, then these types of programs should become more and more popular in Australia, following on from Discovery's amazing growth in South Africa using this model.
From a health perspective, all have different systems with a different role for public and private health, and all are experiencing rising health costs well above inflation. From a personal perspective, my wife much preferred the experience of giving birth in France than the US, and it was much cheaper! There is a lot of innovation in health coming out of the US and France as well as other countries, and so I believe we can learn and adopt where it makes sense in Australia.
One of the key questions in health is how do we fund new emerging and innovative solutions that can benefit the population? I strongly believe that we should be funding solutions that genuinely improve health outcomes, as well as funding solutions that lead to the same health outcomes more efficiently and with a better patient experience - we need both.
Medibank is making decisions today on this basis, and at FOHS I will present this framework including some case studies. The opportunity is how to apply this approach more broadly across the Australian health system if it is to maintain the current strong global rating it has today.
There has never been a more important time for the health industry than now, and actuaries can genuinely contribute to an informed debate of what the future holds.